Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
about
Raltegravir for the treatment of HIV infection in adults and childrenPharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data.Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.Role of raltegravir in the management of HIV-1 infection.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomesSafety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsPharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsA novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteersRaltegravir Pharmacokinetics in Patients on Asunaprevir-DaclatasvirComparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionEffectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Renal effects of novel antiretroviral drugs.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.Divalent metals and pH alter raltegravir disposition in vitro.Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission.Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
P2860
Q24186953-5CEA881C-34D5-4B95-B3ED-E5AE48F1B6E4Q30884873-E37B0463-1521-492C-BB68-6EABB543DF3DQ33585344-3AEF735E-BA71-44CA-B13F-4BBFBBCEFE30Q34993146-0FD16EDE-1C4C-4608-A6C8-14CC32E1713CQ35385630-DF54A561-58D1-4D89-AE06-D2C4DDB614BDQ35557318-D2F7193F-82E2-4B6E-8066-5229D9BE97FDQ35789343-FDFC1F63-189F-44B4-B5EA-91677FCD7134Q35867233-BCAF4FCF-6F9B-4B54-A751-7FB0838E93D8Q35896106-54849B24-42F8-4F52-B38C-BF7C2BC2944FQ36018556-42B4378C-EBFE-43BB-B4E9-E9D5DB36E61BQ36018635-1B68DD1B-1758-413C-BEC3-18671F20C638Q36236691-9977A7B5-1863-4334-807E-DAE0411A2C74Q36276907-FEBC1071-5184-4453-A2F6-C7671AB77AC0Q36290561-AC2CA730-3085-46F7-82A1-5327E616118DQ36396149-AE250A3E-2252-4F63-9F10-E113E5FB2719Q36558501-2ABB5250-44E8-419F-91E6-83773CABF7D4Q37014157-5B810774-8D39-43D6-83A2-2E73F2C5E4FCQ37653463-4F8A7EAB-B6F3-436C-9931-B907BC2C835FQ38166286-5162A199-D8ED-48F9-A11F-52E4961C7620Q38324557-8AC222AE-ED09-4B87-97B2-301DD9EABBBFQ38560855-9120A63F-0C86-4F9D-954F-34A8EF036F81Q38837077-690BE998-2E4F-45CE-99D9-ABE0067BD010Q39074109-92DED1FF-DD18-4A1F-B11D-810FB55B7851Q40199953-6DAD16EF-254B-444E-A22F-690DF1357B36Q40238083-515161FD-7BFF-48CB-B7D9-1A50BA9A40A9Q40492253-D0987C01-5DD5-4985-9E5B-538D1803D57EQ40499890-BF2721A1-C2C1-4C9B-8686-85B579C25B30Q40516335-76E83684-AB7C-4B99-944F-05FC9E3464E2Q41143073-0BD05D4B-9433-467C-A02F-79580B2995F8Q41428049-822B099A-7048-4C01-A51A-187349BDCBFDQ42189797-1602F5F4-9D29-4A18-89C4-600F2C49F51EQ42208301-F0FD3414-6A72-4F2E-B5A0-E531261A6316Q42273377-56048FC4-9862-45BB-B617-26C33E6BEF91Q44500239-FC660D9D-EB8B-44EE-B01C-47A30C835863
P2860
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@en
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@nl
type
label
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@en
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@nl
prefLabel
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@en
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@nl
P2093
P2860
P356
P1476
Clinical pharmacology profile ...... ase strand transfer inhibitor.
@en
P2093
Diana M Brainard
John A Wagner
Julie A Stone
Larissa A Wenning
Marian Iwamoto
P2860
P304
P356
10.1177/0091270010387428
P577
2011-01-05T00:00:00Z